SCHEMBL23930949

SCHEMBL23930949

CC(C)(C)n1nc(N)c2ccc(Cl)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 4/20 0.42
▸ SRC P12931 3/20 0.40
▸ PDGFRA P16234 2/20 0.40
▸ CDK5 Q00535 2/20 0.40
▸ KDR P35968 2/20 0.40
▸ DAPK3 O43293 1/20 0.40
▸ RIPK2 O43353 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ EGFR P00533 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ FYN P06241 1/20 0.40
▸ YES1 P07947 1/20 0.40
▸ LYN P07948 1/20 0.40
▸ HCK P08631 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ FGR P09769 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ PRKACA P17612 1/20 0.40
▸ EPHB2 P29323 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25696301 0.81 RET (0.39) RETSRCPDGFRACDK5KDR
SCHEMBL17108567 0.78 ADORA3 (0.39) MAT2AADORA2AADORA3
SCHEMBL10320957 0.77 NR4A2 (0.42) KDRCYP2C9SMN1; SMN2NR4A2KMO
SCHEMBL4420492 0.75 PRKD3 (0.43) RETSRCKDRRIPK2ABL1
SCHEMBL6480204 0.71 PDGFRA (0.46) PDGFRACDK5PRKACAMAPK8TYRO3
SCHEMBL11751308 0.69 ADORA2A (0.49) PDGFRACDK5CYP1A2CYP2C9CYP2C19
SCHEMBL11749575 0.68 PDGFRA (0.49) PDGFRACDK5SMN1; SMN2TYRO3KMO
SCHEMBL11751709 0.68 PDGFRA (0.49) PDGFRACDK5ABL1SMN1; SMN2NR4A2
SCHEMBL11750409 0.68 PDGFRA (0.49) PDGFRACDK5ABL1SMN1; SMN2TYRO3
SCHEMBL13106495 0.67 MAPK8 (0.41) MAPK8MAPK9MAPK10SMN1; SMN2CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021215545-A1 ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-10-28 — — WO disclosed
Send feedback